Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

May 31, 2010

Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae" Approval obtained as in vitro diagnostic on May 26

Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that it obtained manufacturing and marketing approval of the Streptococcus pneumoniae antigen detection reagent by the immunochromatography method, "RAPIRUN S. pneumoniae" as an in vitro diagnostic on May 26, 2010.

Latest Pharmaceutical Business related News Releases

17 APR 2023

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

30 JAN 2023

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

10 JAN 2023

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae" Approval obtained as in vitro diagnostic on May 26

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan